Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma
Cancers · 15.07.2026 · 18 (14) · 2278
DOI: 10.3390/cancers18142278 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 15.07.2026. Verfasst von Zahra Hasanpour-Segherlou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University of Florida, Gainesville, FL 32608, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common and aggressive primary brain tumor, characterized by poor prognosis and a median survival of 12–18 months despite standard therapies such as surgery, radiation, and temozolomide chemotherapy. Its high cellular heterogeneity, along with complex mechanisms of therapy resistance, presents significant challenges for effective treatment. Conventional systemic chemotherapy is limited by the blood–brain barrier (BBB), systemic toxicity, and insufficient drug penetration into the tumor microenvironment. Emerging therapeutic strategies aim to overcome these barriers through novel chemotherapeutic agents, targeted therapies, immunotherapies, and smart drug delivery systems. Endovascular drug delivery, particularly super-selective intra-arterial cerebral infusion (SSIACI), offers a minimally invasive approach to directly target the tumor vasculature, potentially increasing drug concentration at the tumor site while reducing systemic exposure. Complementary techniques, such as MR-guided focused ultrasound, hyperosmotic disruption, and nanoparticle-based carriers, are being explored to enhance BBB penetration and retention of therapeutics within the tumor. Ongoing clinical trials and translational studies provide insights into optimizing these approaches, with future directions focused on precision medicine, biomarker-driven patient selection, and combination therapies. Integrating endovascular strategies with innovative chemotherapies and immunotherapies may transform GBM management, but further research is required to establish their efficacy and safety in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, University of Florida, Gainesville, FL 32608, USA.
- Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- College of Medicine, University of Florida, Gainesville, FL 32608, USA.
- School of Medicine, Wayne State University, Detroit, MI 48201, USA.
- College of Medicine, Noorda College of Osteopathic Medicine, Provo, UT 84604, USA.
- Victor Babes University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
ORCID-Profile: Zahra Hasanpour-Segherlou, Abdolreza Alikhani, Luca Bertola, Jerick Kim, Clayton Rawson, Andrea Baloi, Brandon Lucke-Wold
Zitieren
APA
Hasanpour-Segherlou, Z., Alikhani, A., Bertola, L., Rupp, C., Haghighi, M., Kim, J., Rawson, C., Baloi, A., Hosseini, F., Pahlevani, M., & Lucke-Wold, B. (2026). Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma. Cancers, 18(14), 2278. https://doi.org/10.3390/cancers18142278
Vancouver
Hasanpour-Segherlou Z, Alikhani A, Bertola L, Rupp C, Haghighi M, Kim J, et al. Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma. Cancers. 2026;18(14):2278. doi:10.3390/cancers18142278
BibTeX
@article{HasanpourSegherlou2026,
author = {Hasanpour-Segherlou, Zahra and Alikhani, Abdolreza and Bertola, Luca and Rupp, Connor and Haghighi, Maya and Kim, Jerick and Rawson, Clayton and Baloi, Andrea and Hosseini, Fatemehsadat and Pahlevani, Mehrdad and Lucke-Wold, Brandon},
title = {Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {14},
pages = {2278},
doi = {10.3390/cancers18142278}
}
EUVIMED